The MitraClip® EXPAND Study
Status: | Recruiting |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/9/2018 |
Start Date: | April 26, 2018 |
End Date: | January 31, 2020 |
Contact: | Leslie Ornelas |
Email: | leslie.ornelas@abbott.com |
Phone: | 408-306-7436 |
A Contemporary, Prospective Study Evaluating Real-world Experience of Performance and Safety for the Next Generation of MitraClip® Devices (EXPAND)
The MitraClip EXPAND Study (A Contemporary, Prospective Study Evaluating Real-world
Experience of Performance and Safety for the Next Generation of MitraClip Devices) is
designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR
System.
Experience of Performance and Safety for the Next Generation of MitraClip Devices) is
designed to confirm the safety and performance of the MitraClip NTR System and MitraClip XTR
System.
The data collected in this study will be used to evaluate device outcomes and characterize
trends in patient selection for MitraClip therapy in contemporary real-world use. Clinical
outcomes and Echocardiographic measures will be assessed in the context of historical data.
The MitraClip EXPAND Study will be conducted on commercial MitraClip NTR System and MitraClip
XTR System that have received CE Mark and/or FDA approval as required.
Up to 1,000 subjects at a maximum of 60 sites in Europe and the US will be in the MitraClip
EXPAND Study.
trends in patient selection for MitraClip therapy in contemporary real-world use. Clinical
outcomes and Echocardiographic measures will be assessed in the context of historical data.
The MitraClip EXPAND Study will be conducted on commercial MitraClip NTR System and MitraClip
XTR System that have received CE Mark and/or FDA approval as required.
Up to 1,000 subjects at a maximum of 60 sites in Europe and the US will be in the MitraClip
EXPAND Study.
Inclusion Criteria:
1. Subjects who give consent for study procedure
2. Subjects eligible to receive the MitraClip per the current approved indications for
use
3. Subjects with Symptomatic MR (≥3+)
Exclusion Criteria:
1. Subjects participating in another clinical study that may impact the follow-up or
results of this study
We found this trial at
5
sites
1000 Blythe Blvd
Charlotte, North Carolina 28203
Charlotte, North Carolina 28203
(704) 355-2000
Principal Investigator: Michael J Rinaldi, MD
Click here to add this to my saved trials
8700 Beverly Blvd # 8211
Los Angeles, California 90048
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Saibal Kar, MD
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
Click here to add this to my saved trials
1215 Lee St
Charlottesville, Virginia 22903
Charlottesville, Virginia 22903
(434) 924-0211
Principal Investigator: Scott Lim, MD
University of Virginia Health System UVA Health System includes a 604-bed hospital, level I trauma...
Click here to add this to my saved trials
800 E 28th St
Minneapolis, Minnesota 55407
Minneapolis, Minnesota 55407
(612) 863-4000
Principal Investigator: Paul Sorajja
Abbott Northwestern Hospital Our hospital has a long and proud history as a health care...
Click here to add this to my saved trials
München, Bavaria 81377
Principal Investigator: Jörg Hausleiter
Click here to add this to my saved trials